On the stock market since 2009, it operates in the world of health and science. It has 175 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
The stock has been running stronger than the market lately.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 14 buys and 8 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $33.00 — 75% above today’s price.
A loss of $3.4M against $0 in annual sales.
This stock swings about 2.6 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, OMER sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: OMER is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (52/100) says the stock isn’t cheap.